Clinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists.

Autor:	Firkins SA; Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: firkins@ccf.org., Yates J; Community Care Institute, Cleveland Clinic Foundation, Cleveland, Ohio., Shukla N; Community Care Institute, Cleveland Clinic Foundation, Cleveland, Ohio., Garg R; Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio., Vargo JJ; Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio., Lembo A; Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
Jazyk:	angličtina
Zdroj:	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2024 Apr 03. Date of Electronic Publication: 2024 Apr 03.
DOI:	10.1016/j.cgh.2024.03.013
Abstrakt:	Glucose-like peptide-1-receptor agonists (GLP-1RAs) have become integral to the management of type 2 diabetes and obesity. GLP-1RAs work in part through delaying gastric emptying, raising concerns about retained gastric contents (RGC) during esophagogastroduodenoscopy (EGD). 1 The American Society of Anesthesiologists currently recommends holding GLP-1RAs for 1 dosing cycle before elective procedures, however, the American Gastroenterological Association (AGA) advocates proceeding with endoscopy in asymptomatic patients adhering to standard perioperative protocols without medication withholding and suggests implementing a liquid diet the day before endoscopy in lieu of stopping the medication. 2,3 This variability in recommendations stems largely from a lack of GLP-1RA outcomes data from which to draw evidence-based conclusions. (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu